1564266-03-0 Usage
Uses
Used in Pharmaceutical Industry:
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2R)-2-aMino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3R,5S)is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs with specific therapeutic properties.
Used in Chemical Research:
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2R)-2-aMino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3R,5S)is also used in chemical research as a model for studying the reactivity and properties of complex organic molecules. It can provide insights into the behavior of similar compounds and contribute to the development of new synthetic methods and strategies.
Used in Impurity Analysis:
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2R)-2-aMino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3R,5S)is used as an impurity in the analysis of Saxagliptin (S143500), a potent and selective reversible inhibitor of dipeptidyl peptidase-4 (DPP-IV) developed for the treatment of type 2 diabetes. The study of this impurity helps in understanding the purity and quality of Saxagliptin, ensuring the safety and efficacy of the drug.
Check Digit Verification of cas no
The CAS Registry Mumber 1564266-03-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,6,4,2,6 and 6 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1564266-03:
(9*1)+(8*5)+(7*6)+(6*4)+(5*2)+(4*6)+(3*6)+(2*0)+(1*3)=170
170 % 10 = 0
So 1564266-03-0 is a valid CAS Registry Number.
1564266-03-0Relevant articles and documents
Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin
Dong, Jizhe,Gong, Yanchun,Liu, Jun,Chen, Xiangfeng,Wen, Xiaoan,Sun, Hongbin
, p. 1383 - 1393 (2014/03/21)
All eight stereoisomers of saxagliptin have been synthesized and evaluated for their inhibitory activity against DPP-IV. It was unambiguously confirmed that the configuration of saxagliptin was critical to potent inhibition of DPP-IV. Docking study was performed to elucidate the configuration-activity relationship of saxagliptin stereoisomers. Tyr662 and Tyr470 have been suggested as the key residues of DPP-IV interacting with the inhibitors. This work provides valuable information for further inhibitor design against DPP-IV.
